Pharmaceutical manufacturers of Riluzole

At Esteve Quimica, we are dedicated to the healthcare sector by providing support for the advancement and commercialization of products that enhance the health of patients. Established in 1966, our company remains privately owned despite being a part of ESTEVE, one of the largest pharmaceutical groups in Spain. Our current focus is on the development and production of small molecule intermediates and active ingredients for innovator companies, operating as a dedicated third-party contract business.

Jiangsu Nhwa Pharmaceutical Co., Ltd. was initially founded in 1978. In year 2008, Nhwa listed on the Shenzhen stock exchange with the stock code 002262. NHWA Pharma integrates R&D, production and sales together, as national psychiatric drugs designated unit, national high-tech enterprise, China’s top 100 pharmaceutical enterprises, national intellectual property rights demonstration unit, national "20 years 20 star" medical quality management enterprise star unit, international environmental certification (ISO14000) confirmed enterprise, the first batch of innovative enterprises in Jiangsu province, and vice President unit of China narcotic drug association.

For more than 40 years, Apotex has been a reputable name in the Canadian pharmaceutical industry, offering patients increased availability to high-quality, cost-effective medications

FARMAK, a.s. is a privately held chemical and pharmaceutical company based in the Czech Republic. The company focuses on the research, development, and production of active pharmaceutical ingredients, chemical products, and specialized chemicals.

Glenmark Pharmaceuticals Limited is a global pharmaceutical company based in Mumbai, India. The company focuses on developing and manufacturing generic and innovative drugs. Their therapeutic areas of expertise include dermatology, respiratory, and oncology. They also manufacture high-quality affordable generic products for the US and European markets through Glenmark Life Sciences, an independent unit of Glenmark Pharmaceuticals.

Euroapi focuses on revolutionizing active component solutions to sustainably fulfill the demands of clients and patients globally. As a prominent figure in active pharmaceutical ingredients, we possess a comprehensive portfolio of around 200 products, encompassing a wide range of technologies, and are constantly developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO). Our 3,350 employees are driven by the commitment to improving access to essential therapies and promoting health

Established in 1973 and based in Mumbai, India, Alkem started its operations as a healthcare marketing firm. Alkem is a major participant in the market for branded and generic drugs in India. The company has a strong presence in various therapeutic segments such as Anti-infective, Gastro-intestinal, Pain Management, Vitamins/Minerals/Nutritions, Central Nervous System, Anti-diabetic, Anti-osteoporosis, Anti-malarial, Cardiovascular, Immunosuppressants, and Nutraceutical segment.

Glenmark Life Sciences Limited is a prominent producer and developer of specialized, high-value, non-generic, active pharmaceutical ingredients (APIs) within chronic therapeutic fields such as heart disease, disorders of the central nervous system, pain management, and diabetes. The corporation is progressively offering CDMO services to various multinational and specialized pharmaceutical firms. It maintains a varied collection of over 137 compounds and delivers its merchandise to clients in India, Europe, North America, Latin America, Japan, and other parts of the globe (ROW).

Products and Services ScinoPharm delivers high-value solutions to its customers with speed and flexibility through a full range of services from API development to commercialization, in addition to cGMP manufacture of materials for clinical trials. Our success is built on the growing partnerships with customers around the world in supply of generic APIs, custom process research services and custom manufacturing services.

Haorui, established in the year 1997, operates as a manufacturer and provider of APIs, pharmaceutical intermediates, veterinary products, and food additives. Furthermore, it aids international pharmaceutical firms in achieving domestic registration for their finished dosage forms to support their global expansion efforts. The company's array of USFDA approved products includes Flumazenil, Granisetron HCl, Granisetron Base, Docetaxel Anhydrous, Irinotecan HCl, and Dasatinib Monohydrate among others. Its headquarters is situated in Shenzhen, China, while it maintains four manufacturing sites in Hubei, Zhejiang, Jiangxi, and Henan. The Hubei facility is recognized for its USFDA and EU GMP approvals, specializing in the production of high potency and oncology materials within a dedicated oncology workshop, meeting OEB 5 material production standards. Haorui prides itself as a dependable partner for all your pharmaceutical needs.

Hubei Haosun Pharmaceutical Co.,Ltd. produces and sells drugs. The Company manufactures and sells irinotecan hydrochloride, docetaxel anhydrous, dasatinib monohydrate, flumazenil, and other products. Hubei Haosun Pharmaceutical markets its products primarily throughout China with limited overseas

Throughout its 50-year history, Apotex has consistently advocated for improved access to affordable medicine, building a solid foundation rooted in positively impacting the patient's journey to health. With significant investment in research and development over the past decade, Apotex improves everyday access to the prescriptions and over-the-counter products regularly found within consumer households. Furthermore, Apotex has emphasized its dedication to patient access through its solid commercial infrastructure, strategic expansions, and significant contributions to healthcare philanthropy by donating to thousands of organizations globally.